A Phase 1 Study of PROT-001.

PHASE1RecruitingINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Healthy

Interventions

DRUG

PROT-001

Orally bioavailable small molecule kinetic stabilizer of lambda light chains (λLCs).

Trial Locations (1)

RECRUITING

Nucleus Network Pty Ltd, Melbourne

All Listed Sponsors

lead

Protego Biopharma Pty Ltd

INDUSTRY